Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 May;10(5):e005207.
doi: 10.1136/jitc-2022-005207.

Celebrating a decade of the Journal for ImmunoTherapy of Cancer

Pedro J Romero  1 , James L Gulley  2 , Patrick Hwu  3 , Mary Dean  4 , Samuel Million-Weaver  4
Affiliations
Editorial

Celebrating a decade of the Journal for ImmunoTherapy of Cancer

Pedro J Romero et al. J Immunother Cancer. 2022 May.
No abstract available

Keywords: Immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Competing interests: PJR—consulting fees: MaxiVax, Enterome, Novigenix; contracted research: Roche pRED, Zurich. PH—consulting fees: Immatics, Dragonfly; ownership interest (less than 5%): Immatics, Dragonfly. JLG—nothing to disclose. MD—nothing to disclose. SMW—shares owned (less than 5%): Editas Medicine, Pacific Biosciences of California.

References

    1. Couzin-Frankel J. Breakthrough of the year 2013. cancer immunotherapy. Science 2013;342:1432–3. 10.1126/science.342.6165.1432 - DOI - PubMed
    1. Spranger S, Koblish HK, Horton B, et al. . Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2014;2:3. 10.1186/2051-1426-2-3 - DOI - PMC - PubMed
    1. Microbial-Based cancer immunotherapy, 2018. Available: https://jitc.bmj.com/pages/collections/microbial_based_cancer_immunother...
    1. Emerging immunotherapeutic agents, 2018. Available: https://jitc.bmj.com/pages/collections/emerging_immunotherapeutic_agents/
    1. Puzanov I, Diab A, Abdallah K, et al. . Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for immunotherapy of cancer (SITC) toxicity management Working group. J Immunother Cancer 2017;5:95. 10.1186/s40425-017-0300-z - DOI - PMC - PubMed

Publication types

Substances